Revolutionizing healthcare one cell at a time.

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, we focus on critical life threatening diseases such as HIV/AIDs, HPV/Cervical Cancer, Hepatitis, organ transplant infections, breast cancer and ovarian cancer.

Our proprietary diagnostic method provides specific molecular details about each and every cell. This technology now made available through IncellDx, is capable of revolutionizing the field of molecular diagnostics, one cell at a time.

Learn More

NEW: IncellDx Signs Agreement with Bristol-Myers Squibb Related to the Development of an Assay for a Companion Diagnostic Test

 

Research article on PLOS One: ‘mRNA and DNA Detection of Human Papillomaviruses in Women of All Ages Attending Two Colposcopy Clinics.*
*HPV OncoTect is CE-IVD marked, not registered in the US
Download PDF.

Read our editorial in Future Virology on the utility of our HIV Viral Reservoirs Assay: http://www.futuremedicine.com/doi/full/10.2217/fvl.12.72 as well as our recent HIV Viral Reservoir research publication referenced in our HIV/AIDS literature citing work using the HIV Viral Reservoir Assay: http://incelldx.com/products/literature/

 

 

IncellDx Receives the 2012 North American Product Leadership Award in the Molecular Diagnostics Market from Frost & Sullivan

 

 

  

IncellDx signs its first CDx Agreement

Bristol-Meyers Squibb and IncellDx have entered into an agreement to develop a companion diagnostic assay around IncellDx’s quantitative InCellCept technology which is intended to identify patients likely to benefit from treatment with a drug that is currently under development.
Read more: IncellDx Signs Agreement with Bristol-Myers Squibb

IncellDx adds Laboratory Network in China

Kindstar Global, the largest esoteric diagnostic testing service in China, will offer a laboratory test based on IncellDx’s molecular diagnostic technology for the detection of oncogenic HPV E6, E7 mRNA in China. IncellDx believes that this agreement will greatly augment its business presence in Asia.
Read more: IncellDx Signs Deal with Kindstar Global to Offer Novel HPV Technology in China

IncellDx adds Laboratory Network in India

New Delhi-based GeneCell Diagnostics will offer IncellDx’s test for detecting oncogenic HPV E6, E7 mRNA through its laboratory partner, CureHealth Diagnostics, which will be the first reference lab in India to offer the test.
Read more: IncellDx Signs Deal with CureHealth Diagnostics to Offer New HPV Technology in India